Lilly, Daiichi Sankyo Suspend Enrollment In Phase II Trials Of Prasugrel

Analysis of “a number of studies” underlies decision to temporarily suspend enrollment to consider dosing changes for the anti-platelet therapy, Lilly tells “The Pink Sheet” DAILY.